Phacilitate Vaccine Forum Fall 2002
Presentations
If you would like to purchase the documentation (Only available on CD) please email team@phacilitate.co.uk and we will confirm a price with you.
DAY 1 - 12th November 2002
Meeting current demand for influenza vaccines while preparing for a possible pandemic
Dr Rakesh Pandey, The Food & Drug Administration
Issues to consider in bringing a new influenza vaccine to the US market
Wayne Pisano, Aventis Pasteur, Inc
Keynote Address
How can the vaccine industry meet influenza vaccine demand?
Technology Presentation Session
Dr Bruce G. Weniger, Centers for Disease Control & Prevention
Chairman’s introduction
Anticipated new technologies to enhance immunization programs
Guiseppe del Giudice, MD, Chiron SpA, What are the advantages of adjuvanted influenza vaccines?
Dr Sanjay Jain, Shire Biologics, Inc
Development of a novel cell-derived split influenza vaccine
Jeroen Medema, Solvay Pharmaceuticals BV
Case study
Exploring alternative manufacturing methods – what is the future for influenza vaccine production?
DAY 2 - 13th November 2002
Overcoming strategic and logistical challenges to address vaccine supply shortages
Dr Diane Simpson, Centers for Disease Control and Prevention (CDC)
Keynote Address
Defining the key areas of unmet medical need
Michael A. Friedman, MD Pharmacia Corporation, PhRMA
Preparing for bioterrorism – building a strategy with the industry to guarantee rapidresponse in a crisis
Dr Lance K. Gordon, VaxGen, Inc
Industry response
Addressing the key drivers which adversely impact the vaccine supply chain
Bill Helming, Pittiglio Rabin Todd & McGrath
Stepping up to the challenges of vaccine manufacturing
Dr Carlo Russo, Merck Research Laboratories
The challenge of developing and manufacturing GMP-compliant new technology vaccines
Richard Holslag, Berna Biotech AG
Addressing the political, regulatory and logistical challenges in developing world vaccine manufacture
Anti-bioterrorism vaccine breakout
Gordon Cameron, Acambis Inc
What are the pros and cons of the anti-bioterrorism vaccine market from the industry perspective?
Robert Kramer, BioPort Corporation
Case study
Bringing an anti-bioterrorism vaccine to market
Dr Paul Chaplin, Bavarian Nordic A/S
Case Study
Hurdles in registering a smallpox vaccine
Dr Peter Hambleton, Centre for Applied Microbiology & Research (CAMR)
Counter-bioterrorism vaccines: European perspectives
Gordon Cameron, Acambis Inc
Panel discussion
How do you build, validate and receive approval for a manufacturing facility in less than five years?
DAY 3 - 14th November 2002
Integrating your project prioritisation and partnering strategies to maximise resource utilisation and access to new technologies
John Lambert, Chiron Corporation
Keynote Address
Reaping the benefits of maintaining a balanced portfolio
Data presentation
Analysing trends in partnering and deal-making in the vaccine industry
Partnering and licensing roundtable
What are the vaccine manufacturers looking for in terms of novel technology? How can the biotech sector maximise the value of their licensing deals through internal technology development?
Moderator:
Allan P. Jarvis Jr., Ph.D, Wyeth Vaccines
Panellists:
Robert S. Becker, Ph.D., MBA, Aventis Pasteur, Inc
David Tomasso, Merck Vaccine Division
Ted A. Marcuccio, Baxter BioScience/Vaccines Division
Novel adjuvants and their applications
Dr Nathalie Garcon, GlaxoSmithKline Biologicals
Chair’s introduction
Heather L. Davis, Ph.D., Coley Pharmaceutical Group
CpG DNA as a universal Th1 immune modulator
Dr David Persing, Corixa Corporation
Taking toll: Synthetic Lipid A mimetics as adjuvants and modulators of
innate immunity
Licensing/partnerships Workshop
Workshop
Attendees to hear varying case studies in the form of joint presentations which explore big pharma-biotech partnerships from both sides of the deal. Discussion and analysis will follow each presentation, with all attendees encouraged to participate
Ted A. Marcuccio, Baxter BioScience/Vaccines Division
and
Nick Higgins, Acambis plc
Case Study 1: Baxter BioScience/Acambis plc
Lallan Giri, BioPort Corporation
Case Study 2: BioPort Corporation
David Gee, Pharmexa A/S
Case Study 3: Pharmexa A/S
DAY 4 - 15th November 2002
Increasing R&D productivity and the efficiency with which vaccines are brought to market
Dr Ronald W. Ellis, Shire Biologics, Inc
Designing a market-focused development and clinical programme
Dr Jerald C. Sadoff, Merck & Co, Inc
Case study
A large-scale phase III clinical trial approach to safety issues associated with rotavirus vaccines
Dr Rino Rappuoli, Chiron Vaccines
Bacterial genomics – from sequence to application
Dr Anne De Groot, EpiVax
Harnessing the ’Immunome’
Bruce L. Roberts, Ph.D., Genzyme Corporation & Genzyme Molecular Oncology &
Dr Jonathan J. Lewis,, Antigenics, Inc
Combining genomics and proteomics to rapidly identify cancer antigens
Workshop: All attendees to compare notes and discuss strategies and solutions
Panellist:
Birger Borregaard, Pharmexa A/S
